"Stacking" in the peptide community means running more than one compound at the same time. Done well, it produces compounding effects. Done badly, it produces cancellation, unpredictable side effects, and data you can't interpret.
Principle 1 — One new variable at a time
If you're evaluating whether a compound works for you, don't add a second new compound in the same cycle. You'll have no way to attribute a result. The only compounds that should run simultaneously on a first cycle are the ones you've individually validated before.
Principle 2 — Understand the receptor story
Two compounds that bind the same receptor can be either synergistic or competitive. The growth-hormone class is the clearest example.
Synergistic pairing: a GHRH analog (CJC-1295, Tesamorelin) with a GH secretagogue (Ipamorelin, GHRP-2). These act on different receptors and produce a larger GH pulse together than either alone. This is why CJC-1295 + Ipamorelin ships as a pre-blended pair.
Competitive pairing: two GHRH analogs simultaneously. They compete for the same receptor. Running Tesamorelin and CJC-1295 together doesn't double the effect — it plateaus near the single-compound ceiling and wastes the second compound.
Principle 3 — Time your injections
Some compounds compete pharmacokinetically even when they don't compete at the receptor level. GH-releasing peptides (GHRPs) should be separated from meals by at least 30 minutes because blood glucose blunts the GH pulse. DSIP should be injected 15–30 minutes before bed to align with natural sleep-onset architecture. GLP-1 agonists are typically once-weekly and timing-agnostic; most others are timing-sensitive.
Principle 4 — Watch the cortisol/prolactin class
GHRP-6 and, to a lesser extent, GHRP-2 can elevate prolactin and cortisol at higher doses. Stacking these with other compounds that push the same axes (Melanotan 2, Kisspeptin) amplifies systemic effects beyond what either compound shows alone. Conservative starting doses help.